May 6th 2024
Despite failing to meet the primary end point, AMO-02 achieved clinically and statistically significant benefit in various functional and objective assessments in the phase 2/3 REACH-CDM trial.
Improving Care for Patients with Motor Complications of Parkinson Disease: Role of Technology and Data
View More
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances
September 15, 2024
Register Now!
Mastering MS: Translating Evidence into Optimal Management Plans
View More
Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care
View More
Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes
View More
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
FDA Allows Additional Enrollment to Foralumab Expanded Access Program
May 4th 2024To date, treatment with foralumab has shown promising results in stabilizing or improving clinical measures without serious adverse effects among patients with non-active secondary progressive multiple sclerosis.
Dosing Underway for Phase 1/2a Study of Autologous Cell Therapy ANPD001 in Parkinson Disease
ASPIRO, an open-label trial, will assess the safety and tolerability of ANPD001, an investigational autologous neuronal replacement therapy being studied as a regenerative therapy for PD.
Advancing Tardive Dyskinesia Treatment With New Sprinkle Formulation of Valbenazine
May 2nd 2024Leslie Citrome, MD, MPH, clinical professor of psychiatry and behavioral sciences at New York Medical College, shared his reaction to the recently approved new sprinkle formulation of valbenazine for patients with tardive dyskinesia.
Understanding the Root Causes of Cognitive Decline in Disadvantaged Neighborhoods
Tanisha Hill-Jarrett, PhD, an assistant professor of neurology at the University of California, San Francisco Memory and Aging Center, discussed the change needed to improve cognitive decline rates in Black women in disadvantaged neighborhoods.
Alzheon Initiates Open-Label Extensions for Phase 2 and 3 Studies of Alzheimer Agent ALZ-801
Phase 2 biomarker trial participants who completed 156 weeks of treatment were offered enrollment into another 52-week extension to continue to observe safety, assessments of plasma biomarkers, and cognitive effects, among others.
Ocrelizumab Gains EU CHMP Positive Opinion for Subcutaneous Formulation to Treat MS
In the phase 3 OCARINA 2 trial, subcutaneous ocrelizumab was non-inferior to intravenous infusion based on concentration levels in the blood, as well as comparable efficacy on relapses and brain lesions.
Applying the Innovation Biodesign Framework to Promote Equity and Green Activity in Dementia Care
April 30th 2024Lassell et al present a use case demonstrating the process of moving an unmet need to the “solution space” of the Innovation Biodesign Framework for addressing a healthcare challenge in a specific at-risk population.
FDA Approves Medtronic’s Inceptiv Closed-Loop Spinal Cord Stimulator
The FDA approval of Medtronic’s spinal cord stimulator makes it the first on the market to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real time for chronic pain.
AI-Powered Neurotech Could Revolutionize Dementia Care and Unlock Communications
Neal K. Shah, CEO of CareYaya Health Technologies, discussed how emerging neurotechnology, such as mobile EEG devices paired with customized AI and machine learning models, is poised to transform the fight against dementia.
Literature Review Demonstrates Ravulizumab’s Superior Efficacy Over Other Approved NMOSD Treatments
In comparison to previously approved treatments like satralizumab and inebilizumab, ravulizumab-treated patients performed significant better on outcomes of first relapse and time to first relapse.
The professor of neurology and pharmacology at the University of California Davis Health Medical Center gave commentary on the FDA approval of Aquestive Therapeutics’ buccal film in pediatric patients with intermittent, stereotypic episodes of frequent seizure activity.
NeurologyLive® Clinician of the Month Spotlight: Kelly Papesh, DNP, APRN, FNP-BC
April 27th 2024As part of our monthly clinician spotlight, NeurologyLive® highlighted movement disorder expert Kelly Papesh, DNP, APRN, FNP-BC, executive director of the Association of Movement Disorder Advanced Practice Providers.